<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548404</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1117</org_study_id>
    <nct_id>NCT01548404</nct_id>
  </id_info>
  <brief_title>Study of REGN668/SAR231893 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the clinical efficacy of repeated subcutaneous (SC) doses of REGN668/SAR231893 in
      adult patients with moderate-to-severe atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in EASI score</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>The primary endpoint is the percent change in Eczema Area and Severity Index (EASI) score from baseline to week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve an IGA score of 0 or 1</measure>
    <time_frame>at week 12</time_frame>
    <description>Proportion of patients who achieve an Investigator's Global Assessment (IGA) score of 0 or 1 at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve ≥50% overall improvement in EASI score</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Proportion of patients who achieve ≥50% overall improvement in EASI score from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EASI score</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Change (or percent change) in EASI score from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGA score</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Change in IGA score from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in % BSA, SCORAD score, Pruritus NRS, and 5-D Pruritus Scale</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Change in % BSA, SCORAD score, Pruritus NRS, and 5-D Pruritus Scale from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs</measure>
    <time_frame>baseline through week 28</time_frame>
    <description>Incidence of treatment emergent adverse events (TEAEs) from baseline through week 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN668/SAR231893</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo matching REGN668/SAR231893</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN668/SAR231893</intervention_name>
    <description>REGN668/SAR231893 for SC dosing will be evaluated in this study.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching REGN668/SAR231893</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The inclusion criteria include, but are not limited to, the following:

          1. Male or female, 18 years or older

          2. Chronic Atopic Dermatitis for at least 3 years

          3. History of inadequate response to a stable (&gt;/= 1 month) regimen of topical
             corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before
             the screening visit

        Exclusion Criteria:

          1. Prior treatment with REGN668

          2. Presence of certain laboratory abnormalities at the screening visit

          3. Treatment with an investigational drug within 8 weeks

          4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit

          5. Certain treatments and medical procedures, undertaken within a particular timeframe
             prior to the baseline visit, preclude eligibility for participation in the study:

          6. Known history of human immunodeficiency virus (HIV) infection

          7. History of malignancy within 5 years before the baseline visit, with certain
             exceptions

          8. Planned surgical procedure during the length of the patient's participation in this
             study

          9. History of clinical parasite infection.

         10. Any medical or psychiatric condition which, in the opinion of the investigator or the
             sponsor's medical monitor, would place the patient at risk, interfere with
             participation in the study, or interfere with the interpretation of study results

         11. Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nachod</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svitavy</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <disposition_first_submitted>August 27, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 11, 2015</disposition_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 22, 2017</submitted>
    <returned>October 12, 2017</returned>
    <submitted>November 13, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

